SGK1 Inhibition
Targeting a genetically validated disease node to reverse stress-induced disease biology.
A stress-activated disease node
OUR SCIENTIFIC APPROACH
Serum- and glucocorticoid-regulated kinase 1 (SGK1) responds to cellular stress. Research to date has implicated chronic SGK1 activation in cardiovascular diseases associated with abnormal electrical and structural changes.
Thryv is developing highly potent, best-in-class SGK1 inhibitors to address the underlying disease biology and residual risk in rare and common cardiac and cardiometabolic diseases, beginning with Long QT Syndrome and heart failure.
CARDIAC FOCUS
-
SGK1 dysregulates cardiac ion channel regulation and electrical activity. SGK1 activation heightens the risk of serious abnormal heart rhythms.
-
SGK1 signals pathways of inflammation, tissue remodeling/fibrosis, and metabolism that adversely affect cardiac structure and function.
-
Thryv’s best-in-class SGK1 inhibitors are in development for high unmet need cardiac and non-cardiac diseases.
Human genetic validation
Lower ventricular SGK1 expression is associated with reduced heart failure risk.
In the UK Biobank, a rare SGK1 variant was significantly associated with heart failure.
These human genetic findings validate SGK1 as a core disease node to target persistent electrical, functional, and structural disease abnormalities in heart failure and cardiomyopathies.
The safety and efficacy of THRV-1268 have not been established. THRV-1268 is investigational; these research programs do not establish a treatment benefit. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g., the FDA in the United States, Health Canada in Canada, or the TGA in Australia).